Log in

OTCMKTS:MVRBF - Medivir AB (publ) Stock Price, Forecast & News

+0.36 (+25.35 %)
(As of 02/28/2020 08:00 AM ET)
Today's Range
Now: $1.78
50-Day Range
MA: $1.44
52-Week Range
Now: $1.78
Volume32,400 shs
Average Volume21,360 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Medivir AB (publ) researches, develops, and sells pharmaceuticals primarily for the treatment of oncology. The company markets Xerclear for use in the treatment of labial herpes under the Zoviduo name. It develops Remetinostat, which has completed phase II clinical trial for treating cutaneous T-cell lymphoma, as well as in phase II clinical trial for treating basal cell carcinoma; and Birinapant that is in phase II clinical trial for treating colorectal cancer. The company also develops MIV-818, which is in phase Ia clinical trial for treating liver cancer; MIV-828, a candidate drug for treating blood cancer; MIV-711, which is in phase II clinical trial for treating osteoarthritis; and MIV-802, a nucleotide-based drug candidate for treating hepatitis C infections. It sells its products in Sweden, the Nordic region, Europe, the United States, and the rest of the world. Medivir AB (publ) was founded in 1988 and is based in Huddinge, Sweden.

Industry, Sector and Symbol

Industry N/A
Phone46 8 54 68 31 00



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A
OptionableNot Optionable

Receive MVRBF News and Ratings via Email

Sign-up to receive the latest news and ratings for MVRBF and its competitors with MarketBeat's FREE daily newsletter.

Medivir AB (publ) (OTCMKTS:MVRBF) Frequently Asked Questions

What is Medivir AB (publ)'s stock symbol?

Medivir AB (publ) trades on the OTCMKTS under the ticker symbol "MVRBF."

What is the consensus analysts' recommendation for Medivir AB (publ)?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medivir AB (publ) in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Medivir AB (publ).

Has Medivir AB (publ) been receiving favorable news coverage?

News stories about MVRBF stock have been trending extremely negative this week, according to InfoTrie. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Medivir AB (publ) earned a news impact score of -4.2 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the next several days. View News Stories for Medivir AB (publ).

Who are Medivir AB (publ)'s key executives?

Medivir AB (publ)'s management team includes the folowing people:
  • Dr. Uli Hacksell, CEO, Pres & Director (Age 69)
  • Ms. Lotta Ferm, Interim Chief Financial Officer (Age 53)
  • Dr. Christina Herder, Exec. VP of Strategic Bus. Devel. (Age 58)
  • Mr. Erik Björk, Exec. Officer (Age 43)
  • Dr. Linda Basse, Chief Medical Officer (Age 63)

How do I buy shares of Medivir AB (publ)?

Shares of MVRBF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Medivir AB (publ)'s stock price today?

One share of MVRBF stock can currently be purchased for approximately $1.78.

What is Medivir AB (publ)'s official website?

The official website for Medivir AB (publ) is http://www.medivir.com/.

How can I contact Medivir AB (publ)?

The company can be reached via phone at 46 8 54 68 31 00.

MarketBeat Community Rating for Medivir AB (publ) (OTCMKTS MVRBF)

Community Ranking:  2.9 out of 5 (star star star)
Outperform Votes:  15 (Thanks for Voting!)
Underperform Votes:  11 (Thanks for Voting!)
Total Votes:  26
MarketBeat's community ratings are surveys of what our community members think about Medivir AB (publ) and other stocks. Vote "Outperform" if you believe MVRBF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MVRBF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/28/2020 by MarketBeat.com Staff

Featured Article: What is a back-end load?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel